<div id="readability-page-1"><p>Total Clarity Wealth Management Inc. bought a new stake in  Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund bought 9,245 shares of the company's stock, valued at approximately $1,247,000.</p><p>A number of other institutional investors have also modified their holdings of ABVX. EverSource Wealth Advisors LLC increased its holdings in shares of  Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock valued at $32,000 after purchasing an additional 369 shares during the period.  First Horizon Corp acquired a new position in shares of  Abivax in the third quarter valued at approximately $36,000.  Bank of America Corp DE increased its holdings in shares of  Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares during the period.  Hantz Financial Services Inc. acquired a new position in shares of  Abivax in the third quarter valued at approximately $52,000.  Finally, WPG Advisers LLC increased its holdings in shares of  Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company's stock valued at $61,000 after purchasing an additional 253 shares during the period. Institutional investors and hedge funds own  47.91% of the company's stock. </p><h2>Abivax Stock Performance</h2><p>Abivax stock opened at $117.38 on Friday. The firm has a market capitalization of $9.31 billion, a price-to-earnings ratio of -21.86 and a beta of 1.68. Abivax SA Sponsored ADR has a fifty-two week low of $5.59 and a fifty-two week high of $148.83. The stock's fifty day moving average is $117.02 and its two-hundred day moving average is $116.30. </p><p>Abivax (NASDAQ:ABVX - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The business had revenue of $0.52 million during the quarter.  As a group, sell-side analysts forecast that  Abivax SA Sponsored ADR will post -3.84 EPS for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of research analysts have recently issued reports on the company. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Abivax in a report on Monday, April 20th. Citigroup  reissued a &#34;market outperform&#34; rating on shares of Abivax in a report on Thursday, January 8th. Oppenheimer  set a $131.00 target price on Abivax in a report on Thursday, January 8th. BTIG Research  reissued a &#34;buy&#34; rating and issued a $150.00 target price on shares of Abivax in a report on Wednesday, February 25th. Finally, Jefferies Financial Group assumed coverage on Abivax in a report on Monday, March 16th. They issued a &#34;buy&#34; rating and a $160.00 target price on the stock. One research analyst  has rated the stock with a Strong Buy rating, thirteen have issued  a Buy rating and one  has issued  a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $137.15.</p><p><b>Read Our Latest Analysis on Abivax</b></p><h2>Abivax Company Profile</h2> (Free Report)<p>Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. </p><p>Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.</p><h2>Read More</h2><ul><li>Five stocks we like better than Abivax</li></ul><p><strong>Want to see what other hedge funds are holding ABVX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abivax Right Now?</h2><p>Before you consider Abivax, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.</p><p>While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABVX

LABU

<p>Total Clarity Wealth Management Inc. acquired 9,245 shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) valued at approximately $1.25 million during the fourth quarter. Other institutional investors also increased their stakes in Abivax, with notable increases from EverSource Wealth Advisors and Bank of America Corp DE. Abivax's stock opened at $117.38, with a market cap of $9.31 billion and a price-to-earnings ratio of -21.86. Analysts have mixed ratings on the stock, with an average target price of $137.15.</p>

Market Beat

Abivax SA

Direxion S&P Biotech Bull 3X

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Horizon

Bank of America

Citigroup

Oppenheimer

Jefferies Financial

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Total Clarity Wealth Management Inc. Acquires Shares of 9,245 Abivax SA Sponsored ADR $ABVX